{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T19:24:23Z","timestamp":1779391463702,"version":"3.53.1"},"reference-count":47,"publisher":"Tech Science Press","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OR"],"published-print":{"date-parts":[[2025]]},"DOI":"10.32604\/or.2024.051586","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T05:08:53Z","timestamp":1724648933000},"page":"885-894","source":"Crossref","is-referenced-by-count":2,"title":["Evaluating the efficacy and safety of Anlotinib in conjunction with stereotactic radiosurgery for small cell lung cancer patients with brain metastases"],"prefix":"10.32604","volume":"33","author":[{"given":"LIZHI","family":"WANG","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HUILIN","family":"SUN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GUIZHI","family":"YU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZEJING","family":"QU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YING","family":"JI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YANPING","family":"CUI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"17807","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1055\/s-0039-1700566","article-title":"Small cell lung cancer: advances in diagnosis and management","volume":"41","author":"Chauhan","year":"2020","journal-title":"Semin Respir Crit Care Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0167-8140(97)00149-7","article-title":"Brain-only metastases of small cell lung cancer; efficacy of whole brain radiotherapy. An EORTC phase II study","volume":"46","author":"Postmus","year":"1998","journal-title":"Radiother Oncol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/cncr.20043","article-title":"Neurologic disorders in 432 consecutive patients with small cell lung carcinoma","volume":"100","author":"Seute","year":"2004","journal-title":"Cancer"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13014-019-1371-4","article-title":"Patterns of brain metastasis immediately before prophylactic cranial irradiation (PCI): implications for PCI optimization in limited-stage small cell lung cancer","volume":"14","author":"Chu","year":"2019","journal-title":"Radiat Oncol Lond Engl"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13014-020-01522-6","volume":"15","author":"Remick","year":"2020","journal-title":"Radiat Oncol Lond Engl"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/acm2.12800","article-title":"Dynamic conformal arcs for lung stereotactic body radiation therapy: a comparison with volumetric-modulated arc therapy","volume":"21","author":"Bokrantz","year":"2020","journal-title":"J Appl Clin Med Phys"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jama.2022.16464","volume":"328","author":"Cheng","year":"2022","journal-title":"JAMA"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.jtho.2023.09.025","article-title":"OA01.04 five-year survival in patients with ES-SCLC treated with Atezolizumab in IMpower133: imbrella a extension study results","volume":"18","author":"Liu","year":"2023","journal-title":"J Thorac Oncol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jtho.2024.03.008","article-title":"Tislelizumab plus platinum and etoposide versus placebo plus platinum and etoposide as first-line treatment for extensive-stage SCLC (RATIONALE-312): a multicenter, double-blind, placebo-controlled, randomized, phase 3 clinical trial","volume":"19","author":"Cheng","year":"2024","journal-title":"J Thorac Oncol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"S1334","DOI":"10.1016\/j.annonc.2023.10.096","article-title":"LBA93 EXTENTORCH: a randomized, phase III trial of toripalimab versus placebo, in combination with chemotherapy as a first-line therapy for patients with extensive stage small cell lung cancer (ES-SCLC)","volume":"34","author":"Cheng","year":"2023","journal-title":"Ann Oncol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.21037\/tlcr-23-641","article-title":"Outcomes of initial therapy for synchronous brain metastases from small cell lung cancer: a single-institution retrospective analysis","volume":"13","author":"Chaung","year":"2024","journal-title":"Transl Lung Cancer Res"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/neuonc\/noac148","article-title":"Hippocampal avoidance prophylactic cranial irradiation (HA-PCI) for small cell lung cancer reduces hippocampal atrophy compared to conventional PCI","volume":"25","author":"de Ruiter","year":"2023","journal-title":"Neuro-Oncol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ijrobp.2023.04.030","article-title":"Sustained preservation of cognition and prevention of patient-reported symptoms with hippocampal avoidance during whole-brain radiation therapy for brain metastases: final results of NRG oncology CC001","volume":"117","author":"Gondi","year":"2023","journal-title":"Int J Radiat Oncol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/neuonc\/noad226","article-title":"Evaluating the heterogeneity of hippocampal avoidant whole brain radiotherapy treatment effect: a secondary analysis of NRG CC001","volume":"26","author":"Cherng","year":"2024","journal-title":"Neuro-Oncol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.3390\/cancers15184622","article-title":"Modern stereotactic radiotherapy for brain metastases from lung cancer: current trends and future perspectives based on integrated translational approaches","volume":"15","author":"Levis","year":"2023","journal-title":"Cancers"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11060-023-04512-2","article-title":"Treatment and survival of patients with small cell lung cancer and brain metastasis","volume":"165","author":"Chiang","year":"2023","journal-title":"J Neurooncol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1001\/jamaoncol.2020.1271","volume":"6","author":"Rusthoven","year":"2020","journal-title":"JAMA Oncol"},{"key":"ref19","first-page":"1063","article-title":". Chinese expert consensus on antiangiogenic drugs for advanced non-small cell lung cancer (2020 Edition)","volume":"42","year":"2020","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"ref20","first-page":"3","article-title":"Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial","volume":"7","author":"Cheng","year":"2024 Jul 11","journal-title":"Nat Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"102543","DOI":"10.1016\/j.eclinm.2024.102543","article-title":"Sintilimab plus anlotinib as second or further-line therapy for extensive disease small cell lung cancer: a phase 2 investigator-initiated non-randomized controlled trial","volume":"70","author":"Ma","year":"2024","journal-title":"eClinicalMedicine"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"5372","DOI":"10.1002\/cam4.5360","article-title":"Efficacy and safety of anlotinib combined with PD-1\/PD-L1 inhibitors as second-line and subsequent therapy in advanced small-cell lung cancer","volume":"12","author":"Yu","year":"2023","journal-title":"Cancer Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.7150\/jca.91701","article-title":"The efficacy and safety of Anlotinib plus etoposide with Cisplatin\/Carboplatin in the first-line treatment of lung cancer: a phase II clinical study","volume":"15","author":"Lv","year":"2024","journal-title":"J Cancer"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1177\/0271678X19859847","article-title":"Controversial roles for dexamethasone in glioblastoma\u2013opportunities for novel vascular targeting therapies","volume":"39","author":"Levis","year":"2019","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12943-019-0950-1","article-title":"Bevacizumab treatment for radiation brain necrosis: mechanism, efficacy and issues","volume":"18","author":"Zhuang","year":"2019","journal-title":"Mol Cancer"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0360-3016(99)00507-6","article-title":"Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05","volume":"47","author":"Shaw","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(04)16250-8","article-title":"Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG, 9508 randomised trial","volume":"363","author":"Andrews","year":"2004","journal-title":"The Lancet"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.3390\/s23073397","article-title":"Accuracy of intracranial pressure monitoring\u2014single centre observational study and literature review","volume":"23","author":"Pelah","year":"2023","journal-title":"Sensors"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1200\/JCO.21.02017","article-title":"Linking the European organisation for research and treatment of cancer item library to the common terminology criteria for adverse events","volume":"40","author":"He","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","article-title":"Validity and reliability of the US national cancer institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"1","author":"Dueck","year":"2015","journal-title":"JAMA Oncol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/neuonc\/nos070","article-title":"Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria","volume":"14","author":"Levis","year":"2012","journal-title":"Neuro-Oncol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.canlet.2020.12.043","article-title":"Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: mechanisms, advances, and challenges","volume":"502","author":"Zhou","year":"2021","journal-title":"Cancer Lett"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"100408","DOI":"10.1016\/j.esmoop.2022.100408","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN","volume":"7","author":"Paz-Ares","year":"2022","journal-title":"ESMO Open"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1001\/jamaoncol.2018.3039","article-title":"Effect of Anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer","volume":"4","author":"Han","year":"2018","journal-title":"JAMA Oncol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1007\/s00262-020-02641-5","article-title":"Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer","volume":"69","author":"Yang","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2176\/nmc.ra.2014-0188","article-title":"Pathophysiology, diagnosis, and treatment of radiation necrosis in the brain","volume":"55","author":"Miyatake","year":"2015","journal-title":"Neurol Med Chir"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41419-020-02749-7","article-title":"Anlotinib suppresses tumor progression via blocking the VEGFR2\/PI3K\/AKT cascade in intrahepatic cholangiocarcinoma","volume":"11","author":"Song","year":"2020","journal-title":"Cell Death Dis"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/neuonc\/noaa236","article-title":"The efficacy of anlotinib instead of glucocorticoids for edema induced by brain metastases in NSCLC patients with anti-PD1\/PDL-1 immunotherapy","volume":"23","author":"Zhuang","year":"2021","journal-title":"Neuro-Oncol"},{"key":"ref40","first-page":"930","article-title":"The safety and efficacy of anlotinib in combination with stereotactic radiotherapy for the treatment of brain metastases from non-small cell lung cancer","volume":"102","author":"Wang","year":"2022 Apr 5","journal-title":"Natl Med J China"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"e870","DOI":"10.1634\/theoncologist.2019-0838","article-title":"The impact of Anlotinib on brain metastases of non-small cell lung cancer: post hoc analysis of a phase III randomized control trial (ALTER0303)","volume":"25","author":"Jiang","year":"2020","journal-title":"Oncologist"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1039\/C8BM01350K","article-title":"Attempts to strengthen and simplify the tumor vascular normalization strategy using tumor vessel normalization promoting nanomedicines","volume":"7","author":"Du","year":"2019","journal-title":"Biomater Sci"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.ijrobp.2018.04.068","article-title":"Bevacizumab monotherapy reduces radiation-induced brain necrosis in nasopharyngeal carcinoma patients: a randomized controlled trial","volume":"101","author":"Xu","year":"2018","journal-title":"Int J Radiat Oncol"},{"key":"ref44","first-page":"3770","article-title":"Anlotinib combined with cranial radiotherapy for non-small cell lung cancer patients with brain metastasis: a retrospectively, control study","volume":"13","author":"He","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref45","first-page":"455","article-title":"Peri-radiosurgical administration of bevacizumab improves radiographic response to single and fractionated stereotactic radiosurgery for large brain metastasis","volume":"153","author":"He","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMoa071780","article-title":"Prophylactic cranial irradiation in extensive small-cell lung cancer","volume":"357","author":"Slotman","year":"2007","journal-title":"N Engl J Med"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(17)30230-9","article-title":"Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial","volume":"18","author":"Takahashi","year":"2017","journal-title":"Lancet Oncol"}],"container-title":["Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdn.techscience.cn\/files\/or\/2025\/TSP_OR-33-4\/OncolRes-33-04-51586\/OncolRes-33-51586.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T06:31:31Z","timestamp":1763101891000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.techscience.com\/or\/v33n4\/60023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":47,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025]]},"published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.32604\/or.2024.051586","relation":{},"ISSN":["1555-3906"],"issn-type":[{"value":"1555-3906","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}